Fu P

机构：Case Western Reserve University

发表论文 9 篇 · 总被引 3 次 · h-index 1

代表论文

Spatial transcriptomics–guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer: CHAARTED trial (ECOG-ACRIN E3805). (2026 · Journal of Clinical Oncology · 被引 1)
Spatial transcriptomics-guided pathology biomarker as a predictor of benefit of adjuvant docetaxel in high-risk localized prostate cancer: NRG/RTOG 0521 (NCT00288080). (2026 · Journal of Clinical Oncology · 被引 1)
NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study (2026 · Endocrine Related Cancer · 被引 1)
A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy. (2026 · Journal of Clinical Oncology)
Baseline CT-derived QVT score as predictor of bevacizumab benefit in advanced non-squamous NSCLC: A retrospective biomarker analysis of SWOG S0819. (2026 · Journal of Clinical Oncology)
An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304). (2026 · Journal of Clinical Oncology)